YEAR-END REPORT 2007 January - December 2007 • Group revenues from sales of goods and royalties amounted to 1,317.6 (1,303.7) MSEK during the year. • Growth within the Esthetics product area was 13 percent and revenues amounted to 1,073.0 (950.6) MSEK. • When Restylane Perlane was approved for sales in the USA (May 2007) Q-Med received 29.1 MUSD (199.7 MSEK) from Medicis. • Operating income amounted to 370.5 (300.0) MSEK. • Income after tax amounted to 315.4 (212.4) MSEK. • Earnings per share after full dilution were 3.17 (2.14) SEK. October - December 2007 • Group revenues from sales of goods and royalties amounted to335.9 (331.5) MSEK and operating income amounted to -10.7 (40.8) MSEK. • Income after tax amounted to -13.7 (25.7) MSEK. Important events after the end of the year • An international distribution agreement has been entered into with Palomar Medical Technologies Inc. with regard to the marketing, sales and distribution of Palomar's products outside North America (January 2008). • Q-Med has decided to terminate production and sales of ZUIDEX and will offer DEFLUX for cystoscopic treatment of stress urinary incontinence (February 2008). Queries should be addressed to: Bengt Ågerup, President and CEO Tel: +46 (0)70-974 9025 Madelene Sandgren, Director Investor Relations and Corporate Communications Tel:+46 ( 0)70-974 9015 Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane™ for body contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee joints, Deflux™ for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, Zuidex™ for the treatment of stress urinary incontinence in women, and Solesta™ for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.
YEAR-END REPORT 2007
| Source: Q-Med AB